OTC:FOSUY

It's time to get a better look at Fosun

Retrieved on: 
金曜日, 5月 31, 2024
Insurance, CPC, FTG, Uncertainty, HKEX, Central committee, Communist party, COVID-19, Goldman Sachs, Intelligence, Investment, Happiness, UBS, Hang Seng Index, Sale, Optimism, Deutsche Bank, Fosun Pharma, HAL, Growth, ABN AMRO, ABN, Chinese Communist Party, Morgan Stanley, Attention, AMRO Bank, HSBC, Tourism, Cryptocurrency

As of 27 March 2024, Fosun International's share price had dropped to a 10-year low of HK$3.93.

Key Points: 
  • As of 27 March 2024, Fosun International's share price had dropped to a 10-year low of HK$3.93.
  • Nonetheless, a re-rating of Fosun is likely to have a greater impact than its recent solid performance.
  • Therefore, when the headwinds hit in 2022, Fosun was better equipped to withstand the impact.
  • Its four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group (FTG), all saw significant revenue growth, contributing 72% of the total revenue.

Fosun Sells German Private Bank HAL and Retains HAFS Asset Servicing Business, Aligns with its Asset-Light Strategy

Retrieved on: 
火曜日, 5月 28, 2024
FTG, HKEX, Trastuzumab, S&P, Happiness, UBS, Ecosystem, Sale, Club Med, Marketing, IRR, Fosun Pharma, Complementarity, HAL, Overweight, Growth, ABN AMRO, ABN, Citibank, Face, AMRO Bank, Acquisition, Cell, Gene, HAFS, Tourism, Bank

HAFS is one of the ten major asset servicing companies in German-speaking regions.

Key Points: 
  • HAFS is one of the ten major asset servicing companies in German-speaking regions.
  • The announcement indicates that the sale is part of Fosun's ongoing efforts to optimize its asset portfolio and focus on asset-light operations.
  • It is worth noting that based on the transaction consideration of EUR670.3 million, the project is expected to yield double-digit IRR for Fosun.
  • Fosun International will continue to hold the asset servicing business, which is an asset-light "cash cow" operation.

Citi, UBS, GS view positive on Fosun's core business-focused strategy

Retrieved on: 
火曜日, 4月 23, 2024
Goldman Sachs, HKEX, Fosun Pharma, GS, BCP, Research, UBS, Fosun International, Happiness, Research report, Growth

Goldman Sachs gave Fosun International a target price of HK$4.90, representing an upside of over 13%.

Key Points: 
  • Goldman Sachs gave Fosun International a target price of HK$4.90, representing an upside of over 13%.
  • Fosun International's businesses in Health, Happiness and Wealth segments are expected to keep on growing steadily in the future.
  • Citi Research also issued a report in which it expressed its optimistic views about Fosun International's market outlook.
  • Citi Research gave Fosun a "Buy" rating, with a target price of HK$ 6.30, an expected increase of approximately 57%.